AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29072514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 drops, three times a day for 8 weeks)
Number of subjects: 60
Study 29072514 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract
Number of subjects: 60
Study 28388933 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c test and brief standardized counseling
Number of subjects: 315
Study 28388933 — intervention group
Group type: COMPARATOR
Intervention: Brochure about clinical preventive services
Number of subjects: 315
Study 26164495 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, twice daily for 4 weeks
Number of subjects: 12
Study 26164495 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, twice daily for an additional 4 weeks
Number of subjects: 12
Study 26164495 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis during PPI use
Number of subjects: 12
Study 24131496 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT Therapy (HPI)
Number of subjects: 0
Study 24131496 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 21960073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (MAC=0.8‐1) and N(2)O 50%
Number of subjects: 60
Study 21960073 — intervention group
Group type: COMPARATOR
Intervention: TIVA (propofol at 100‐150 mg/kg/min and remifentanil at 2.0 mg/kg/min)
Number of subjects: 60
Study 17880950 — intervention group
Group type: COMPARATOR
Intervention: Low dose step‐up regimen
Number of subjects: 225
Study 17880950 — intervention group
Group type: COMPARATOR
Intervention: Step‐down regimen
Number of subjects: 225
Study 17880950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential step‐up/step‐down regimen
Number of subjects: 225
Study 16797240 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day and Aspirin 100 mg/day
Number of subjects: 170
Study 16797240 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 170
Study 12771613 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 40
Study 10688831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin (Refludan, bolus: 0.1 mg/kg, infusion: 0.1 mg/kg/h for 5 hours)
Number of subjects: 24
Study 10688831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9354207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.m.
Number of subjects: 24
Study 9354207 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 24
Study 8407854 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine
Number of subjects: 18
Study 8407854 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 18
Study 3101396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclabil
Number of subjects: 120
Study 3101396 — intervention group
Group type: COMPARATOR
Intervention: SH D 386 F
Number of subjects: 120
Study 29905646 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-cognitive coordination workplace intervention
Number of subjects: 28
Study 29905646 — intervention group
Group type: COMPARATOR
Intervention: Classical workplace health enhancement training
Number of subjects: 28
Study 26522372 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM)
Number of subjects: 82
Study 26522372 — intervention group
Group type: COMPARATOR
Intervention: Conventional Method (CM)
Number of subjects: 82
Study 26522372 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM) in transgastric puncture group
Number of subjects: 82
Study 26522372 — intervention group
Group type: COMPARATOR
Intervention: Conventional Method (CM) in transgastric puncture group
Number of subjects: 82
Study 26522372 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-Knocking Method (DKM) in transduodenal puncture group
Number of subjects: 82
Study 26522372 — intervention group
Group type: COMPARATOR
Intervention: Conventional Method (CM) in transduodenal puncture group
Number of subjects: 82
Study 24895815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track (FT) program
Number of subjects: 297
Study 22117186 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 40
Study 22117186 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 40
Study 22117186 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 40
Study 22117186 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 21084620 — intervention group
Group type: EXPERIMENTAL
Intervention: High criterion for signaling errors
Number of subjects: 0
Study 21084620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low criterion for signaling errors
Number of subjects: 0
Study 21084620 — intervention group
Group type: COMPARATOR
Intervention: Ne/ERN
Number of subjects: 0
Study 18958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music training
Number of subjects: 0
Study 18958177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16355622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fengbei Huayu recipe (FHR) twice a day for 8 weeks
Number of subjects: 72
Study 16355622 — intervention group
Group type: COMPARATOR
Intervention: Conventional hypoglycemic agents and hypotensor
Number of subjects: 72
Study 16355622 — intervention group
Group type: COMPARATOR
Intervention: Both groups (FHR and control)
Number of subjects: 72
Study 14596580 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized behavioral treatments
Number of subjects: 3
Study 14596580 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 3
Study 11279324 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg daily)
Number of subjects: 52
Study 11279324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10-20 mg daily)
Number of subjects: 52
Study 8688397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclosure of the visceral and parietal peritoneum
Number of subjects: 280
Study 8688397 — intervention group
Group type: COMPARATOR
Intervention: Closure of the visceral and parietal peritoneum
Number of subjects: 280
Study 1885945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 84
Study 1885945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 6337032 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (average 0.24 mg/day)
Number of subjects: 16
Study 6337032 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (average 105 mg/day)
Number of subjects: 16
Study 6337032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30903972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 53
Study 30903972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 53
Study 30903972 — intervention group
Group type: COMPARATOR
Intervention: SIT and CAT (combined)
Number of subjects: 53
Study 28976423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational advice service (intervention arm)
Number of subjects: 338
Study 28976423 — intervention group
Group type: COMPARATOR
Intervention: Best current primary care (control arm)
Number of subjects: 338
Study 26374852 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular septal pacing (RVS)
Number of subjects: 263
Study 26374852 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 263
Study 25217169 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual parent‐only CBT intervention (PCBT, n=18)
Number of subjects: 31
Study 25217169 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL, n=13)
Number of subjects: 31
Study 25217169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample of treated participants
Number of subjects: 31
Study 25217169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat sample
Number of subjects: 31
Study 23094900 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 41 ml of levobupivacaine 0.5 % + 1 ml magnesium sulfate (150 mg)
Number of subjects: 80
Study 23094900 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV: 41 ml of levobupivacaine 0.25 % + 1 ml magnesium sulfate (150 mg)
Number of subjects: 80
Study 23094900 — intervention group
Group type: COMPARATOR
Intervention: Group I: 41 ml of levobupivacaine 0.5 % + 1 ml NaCl 0.9 %
Number of subjects: 80
Study 23094900 — intervention group
Group type: COMPARATOR
Intervention: Group III: 41 ml of levobupivacaine 0.25 % + 1 ml NaCl 0.9 %
Number of subjects: 80
Study 20507548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (questionnaire based intervention programme)
Number of subjects: 741
Study 20507548 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 741
Study 18843927 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (added to general body conditioning)
Number of subjects: 30
Study 18843927 — intervention group
Group type: COMPARATOR
Intervention: General body conditioning (control group)
Number of subjects: 30
Study 16137437 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 266
Study 16137437 — intervention group
Group type: COMPARATOR
Intervention: Weekly epirubicin
Number of subjects: 266
Study 12208801 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 100
Study 12208801 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 100
Study 12208801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with HF
Number of subjects: 100
Study 10915232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem retard (100-200mg once daily)
Number of subjects: 13
Study 10915232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8864318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (200 mg to 1600 mg)
Number of subjects: 0
Study 8864318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (up to 1600 mg)
Number of subjects: 0
Study 1636340 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep method
Number of subjects: 2655
Study 6432325 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ketoprofen
Number of subjects: 30
Study 6432325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of lysine acetylsalicylate
Number of subjects: 30
Study 6432325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31174583 — intervention group
Group type: EXPERIMENTAL
Intervention: No drains placed (experimental group)
Number of subjects: 252
Study 31174583 — intervention group
Group type: COMPARATOR
Intervention: At least one passive intra-abdominal drain placed (control group)
Number of subjects: 252
Study 28967099 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients
Number of subjects: 93
Study 28967099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 27974950 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 20mg/kg/day
Number of subjects: 10
Study 27974950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 24661817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin
Number of subjects: 116
Study 24661817 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 116
Study 23046784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 30
Study 23046784 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling
Number of subjects: 30
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (overall)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (carotid VWV regression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (carotid VWV progression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure change (carotid VWV regression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure change (carotid VWV progression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine change (carotid VWV regression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine change (carotid VWV progression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1 change (carotid VWV regression)
Number of subjects: 140
Study 20194883 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1 change (carotid VWV progression)
Number of subjects: 140
Study 17507321 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) regimen
Number of subjects: 96
Study 16133484 — intervention group
Group type: COMPARATOR
Intervention: Non-ionic Gd-DTPA-BMA/gadodiamide (0.1 mmol/kg body weight)
Number of subjects: 40
Study 16133484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic Gd-DTPA/gadopentetate (0.1 mmol/kg body weight)
Number of subjects: 40
Study 11896513 — intervention group
Group type: EXPERIMENTAL
Intervention: > or =3 courses of antenatal corticosteroids (ANCS)
Number of subjects: 595
Study 11896513 — intervention group
Group type: COMPARATOR
Intervention: 1 or 2 courses of antenatal corticosteroids (ANCS)
Number of subjects: 595
Study 12166718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigy Condensable (P)
Number of subjects: 36
Study 12166718 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite (D)
Number of subjects: 36
Study 9822949 — intervention group
Group type: EXPERIMENTAL
Intervention: six-month behavioral weight loss intervention, delivered via correspondence
Number of subjects: 90
Study 9822949 — intervention group
Group type: COMPARATOR
Intervention: no-treatment control group
Number of subjects: 90
Study 7860418 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 4 mg/day testosterone replacement
Number of subjects: 2
Study 7860418 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 8 mg/day testosterone replacement
Number of subjects: 2
Study 7860418 — intervention group
Group type: COMPARATOR
Intervention: Control period (3 weeks)
Number of subjects: 2
Study 7860418 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment period (9 weeks)
Number of subjects: 2
Study 2468962 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 11195 (200 mg orally)
Number of subjects: 6
Study 2468962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg orally)
Number of subjects: 6
Study 2468962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PK 11195 and Nicardipine
Number of subjects: 6
Study 2468962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 913294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 36
Study 913294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-triamterene (25 and 50 mg/d)
Number of subjects: 36
Study 913294 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg/d)
Number of subjects: 36
Study 913294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-triamterene added to Propranolol
Number of subjects: 36
Study 6782605 — intervention group
Group type: EXPERIMENTAL
Intervention: IV physostigmine administration
Number of subjects: 0
Study 6782605 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31295292 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic footwear with a rigid rocker sole
Number of subjects: 51
Study 31295292 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic footwear with semi-rigid sole (control)
Number of subjects: 51
Study 31295292 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic footwear with a rigid rocker sole (among >60% adherence group)
Number of subjects: 51
Study 30566019 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 30566019 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 27336726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (400 mg/day) plus letrozole (2.5 mg/day)
Number of subjects: 14
Study 27336726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day) plus letrozole (2.5 mg/day)
Number of subjects: 14
Study 27336726 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/day) alone
Number of subjects: 14
Study 25027304 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI at 14.4, 28.8, 57.6, and 115.2 μg
Number of subjects: 33
Study 25027304 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 33
Study 25027304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (TIO) 18 μg
Number of subjects: 33
Study 22070446 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI by passive straightening of the uterus by means of bladder filling
Number of subjects: 460
Study 22070446 — intervention group
Group type: COMPARATOR
Intervention: IUI performed with an empty bladder (control)
Number of subjects: 460
Study 22070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy IUI (full bladder)
Number of subjects: 460
Study 22070446 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult IUI (empty bladder)
Number of subjects: 460
Study 20417445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care programme managed by trained nurses; intervention lasted for 1 year with visits every 6 weeks for standardized BP measurement, self‐measurement training, risk factor checks and advice on BP reduction.
Number of subjects: 200
Study 20417445 — intervention group
Group type: COMPARATOR
Intervention: Usual care; control group.
Number of subjects: 200
Study 18577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlition (contains a-lipoic acid) used in neuroprotective therapy for chronic brain ischemia
Number of subjects: 0
Study 15844495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 mcg twice daily, commencing 6 weeks after FESS
Number of subjects: 109
Study 15844495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 14624183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 47
Study 14624183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 20 mg every 8 hours
Number of subjects: 11733
Study 10482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 80 mg every 8 hours
Number of subjects: 11733
Study 10482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 120 mg every 8 hours
Number of subjects: 11733
Study 10482177 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 8 hours
Number of subjects: 11733
Study 10482177 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (cariporide and placebo)
Number of subjects: 11733
Study 8728458 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-rotation test
Number of subjects: 42
Study 8728458 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 42
Study 1867090 — intervention group
Group type: EXPERIMENTAL
Intervention: Materially deprived children
Number of subjects: 234
Study 1867090 — intervention group
Group type: COMPARATOR
Intervention: Other children
Number of subjects: 234
Study 6634348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 received a random order of six numbers (5, 10, 15, 20, 25, 30) for magnitude production.
Number of subjects: 20
Study 6634348 — intervention group
Group type: COMPARATOR
Intervention: Group 2 received the same random series of six numbers as Group 1, but with additional numbers interspersed to present an expanded range.
Number of subjects: 20
Study 30876982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS at 2 mA
Number of subjects: 20
Study 30876982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS at 1 mA
Number of subjects: 20
Study 30876982 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 29995455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin‐α 550 mg twice daily plus lactulose
Number of subjects: 0
Study 29995455 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone
Number of subjects: 0
Study 27584836 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based integrated intervention (social skills training plus Tai-chi)
Number of subjects: 244
Study 27584836 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment alone (MTA group)
Number of subjects: 244
Study 24527846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% pilocarpine mouthwash
Number of subjects: 60
Study 24527846 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study 22197676 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 586
Study 22197676 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 586
Study 22197676 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 586
Study 19395187 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant ADT before RT
Number of subjects: 378
Study 19395187 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 months of neoadjuvant ADT before RT
Number of subjects: 378